IMPACT Therapeutics boosts share capital by 2.30 % through full over-allotment option exercise
Bulletin Express
Yesterday
IMPACT Therapeutics, Inc. (IMPACT THERAP-B) reported that the joint global coordinators fully exercised the over-allotment option on 10 June 2026, resulting in the issuance and allotment of 6.30 million new H shares at HKD 20.10 each.
The transaction expands the company’s issued H-share capital from 276.17 million to 282.46 million shares, marking a 2.30 % increase. No treasury shares were involved, and the company confirmed that all regulatory conditions and internal approvals were satisfied, with all subscription monies received.
Based on the disclosed issue price and share count, the offering amounts to approximately HKD 126.56 million, further strengthening IMPACT Therapeutics’ capital base.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.